Gensight Biologics Financials
| SIGHT Stock | EUR 0.24 0.02 7.69% |
Gensight |
Gensight Biologics Stock Summary
Gensight Biologics competes with DBV Technologies, Inventiva, Abivax SA, and Nanobiotix. GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France. GENSIGHT BIOLOGICS is traded on Paris Stock Exchange in France.| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0013183985 |
| Business Address | 74, rue du |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.gensight-biologics.com |
| Phone | 33 1 76 21 72 20 |
| Currency | EUR - Euro |
You should never invest in Gensight Biologics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Gensight Stock, because this is throwing your money away. Analyzing the key information contained in Gensight Biologics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Gensight Biologics Key Financial Ratios
Gensight Biologics' financial ratios allow both analysts and investors to convert raw data from Gensight Biologics' financial statements into concise, actionable information that can be used to evaluate the performance of Gensight Biologics over time and compare it to other companies across industries.Gensight Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Gensight Biologics's current stock value. Our valuation model uses many indicators to compare Gensight Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gensight Biologics competition to find correlations between indicators driving Gensight Biologics's intrinsic value. More Info.Gensight Biologics SA is rated third in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Gensight Biologics' earnings, one of the primary drivers of an investment's value.Gensight Biologics Systematic Risk
Gensight Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Gensight Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Gensight Biologics correlated with the market. If Beta is less than 0 Gensight Biologics generally moves in the opposite direction as compared to the market. If Gensight Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Gensight Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Gensight Biologics is generally in the same direction as the market. If Beta > 1 Gensight Biologics moves generally in the same direction as, but more than the movement of the benchmark.
Gensight Biologics March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Gensight Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Gensight Biologics SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Gensight Biologics SA based on widely used predictive technical indicators. In general, we focus on analyzing Gensight Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Gensight Biologics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 31.5 | |||
| Value At Risk | (6.90) | |||
| Potential Upside | 4.17 |
Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.